

BioAlliance Pharma strengthens its financial resources with the support of its top shareholder

Paris, July 18, 2014 – BioAlliance Pharma SA (Euronext Paris - BIO), an innovative Company specialized in the development of drugs in orphan oncology diseases, today announced the setup of a €10 million loan granted by its top shareholder, Financière de la Montagne.

A BioAlliance Pharma shareholder since 2008, today its top shareholder and member of its Board of Directors, Financière de la Montagne thus confirms its commitment to the Company.

This loan helps strengthen the financial resources of BioAlliance Pharma, and those of Onxeo following completion of the company's merger with Topotarget. In particular, the loan supports its R&D programs, including the international phase III clinical trial with Livatag® in primary liver cancer.

The loan is granted for a one-year period, until July 31st 2015, in the form of a shareholders' current account and will bear a 15% interest payable at maturity. Capital and interest are repayable in cash, or in shares in case the company launches a capital increase prior to the end of the loan agreement. The debt incorporated for the subscription to the capital increase would then be increased by a 25% premium.

« With this funding operation, Financière de la Montagne demonstrates once again its confidence in the Company's strategy, capacity for growth and value creation, and I would like to warmly thank our leading shareholder for this », comments Judith Greciet, CEO of BioAlliance Pharma. "This support allows us to fully commit to our vision to become a leader in the field of orphan oncology diseases with the creation of Onxeo".

About Onxeo

BioAlliance Pharma and Topotarget are merging to create Onxeo, following approval of shareholders of both companies end of June 2014.

Onxeo aims to become a leading orphan oncology company. With a portfolio of advanced programs targeting severe orphan oncology diseases for which there is an unmet medical need, Onxeo will offer increased market attractiveness, notably towards specialized international investors, using its scale and significant footprint as a biotechnology leader with a growing portfolio of high value-added products.

About Topotarget

Topotarget (NASDAQ OMX: TOPO) is a Danish-based biopharmaceutical company headquartered in Copenhagen, Denmark, dedicated to clinical development and registration of oncology products. In collaboration with Spectrum Pharmaceuticals, Inc., Topotarget focuses on the development of its lead drug candidate, belinostat, which has shown positive results in the treatment of hematological malignancies and solid tumors, obtained by both mono- and combination therapy. For more information, please refer to www.topotarget.com.

About BioAlliance Pharma

Dedicated to cancer treatments with a focus on resistance targeting and orphan products, BioAlliance Pharma conceives and develops innovative products for orphan or rare diseases.

Created in 1997 and introduced to the Euronext Paris market in 2005, BioAlliance Pharma's ambition is to become a leading player in these fields by coupling innovation to patient needs. The company's teams have the key competencies required to identify, develop and register drugs in Europe and the USA.

BioAlliance Pharma has developed an advanced product portfolio:

Orphan Oncology products

Livitag[®] (Doxorubicin Transdrug[™]) (primary liver cancer): Phase III on going

Validive[®] (Clonidine Lauriad[®]) (mucositis): Phase II on going

AMEP[®]/Synfoldin (invasive melanoma): Clinical and Preclinical Phase

For more information, visit the BioAlliance Pharma web site at www.bioalliancepharma.com

Disclaimer

This communication expressly or implicitly contains certain forward-looking statements concerning BioAlliance Pharma SA and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of BioAlliance Pharma SA to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. BioAlliance Pharma SA is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

For a discussion of risks and uncertainties which could cause actual results, financial condition, performance or achievements of BioAlliance Pharma SA to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the 2013 Reference Document filed with the AMF on April 7, 2014, which is available on the AMF website (<http://www.amf-france.org>) or on BioAlliance Pharma SA's website (www.bioalliancepharma.com).

BioAlliancePharma SA

Judith Greciet, CEO

judith.greciet@bioalliancepharma.com

Nicolas Fellmann, CFO

nicolas.fellmann@bioalliancepharma.com

Tel.: +33 1 45 58 76 00

ALIZE RP

Caroline Carmagnol

+33 6 64 18 99 59

bap@alizerp.com

